|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: VPS52 |
Gene summary for VPS52 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | VPS52 | Gene ID | 6293 |
| Gene name | VPS52 subunit of GARP complex | |
| Gene Alias | ARE1 | |
| Cytomap | 6p21.32 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4DS44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6293 | VPS52 | LZE4T | Human | Esophagus | ESCC | 5.27e-06 | 1.89e-01 | 0.0811 |
| 6293 | VPS52 | LZE7T | Human | Esophagus | ESCC | 2.17e-05 | 3.14e-01 | 0.0667 |
| 6293 | VPS52 | LZE8T | Human | Esophagus | ESCC | 2.19e-05 | 1.58e-01 | 0.067 |
| 6293 | VPS52 | LZE20T | Human | Esophagus | ESCC | 2.64e-08 | 3.08e-01 | 0.0662 |
| 6293 | VPS52 | LZE22T | Human | Esophagus | ESCC | 1.98e-04 | 2.82e-01 | 0.068 |
| 6293 | VPS52 | LZE24T | Human | Esophagus | ESCC | 1.75e-06 | 1.92e-01 | 0.0596 |
| 6293 | VPS52 | LZE21T | Human | Esophagus | ESCC | 1.62e-04 | 2.46e-01 | 0.0655 |
| 6293 | VPS52 | P1T-E | Human | Esophagus | ESCC | 1.21e-06 | 2.77e-01 | 0.0875 |
| 6293 | VPS52 | P2T-E | Human | Esophagus | ESCC | 4.75e-22 | 4.24e-01 | 0.1177 |
| 6293 | VPS52 | P4T-E | Human | Esophagus | ESCC | 7.72e-09 | 2.13e-01 | 0.1323 |
| 6293 | VPS52 | P5T-E | Human | Esophagus | ESCC | 1.14e-06 | 1.34e-01 | 0.1327 |
| 6293 | VPS52 | P8T-E | Human | Esophagus | ESCC | 2.60e-12 | 2.34e-01 | 0.0889 |
| 6293 | VPS52 | P9T-E | Human | Esophagus | ESCC | 4.05e-10 | 1.74e-01 | 0.1131 |
| 6293 | VPS52 | P10T-E | Human | Esophagus | ESCC | 3.30e-10 | 2.02e-01 | 0.116 |
| 6293 | VPS52 | P11T-E | Human | Esophagus | ESCC | 1.82e-10 | 4.12e-01 | 0.1426 |
| 6293 | VPS52 | P12T-E | Human | Esophagus | ESCC | 5.90e-16 | 3.68e-01 | 0.1122 |
| 6293 | VPS52 | P15T-E | Human | Esophagus | ESCC | 1.05e-14 | 2.77e-01 | 0.1149 |
| 6293 | VPS52 | P16T-E | Human | Esophagus | ESCC | 5.30e-25 | 4.55e-01 | 0.1153 |
| 6293 | VPS52 | P17T-E | Human | Esophagus | ESCC | 3.16e-03 | 2.46e-01 | 0.1278 |
| 6293 | VPS52 | P19T-E | Human | Esophagus | ESCC | 2.34e-05 | 4.38e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006896 | Liver | HCC | Golgi to vacuole transport | 15/7958 | 20/18723 | 3.31e-03 | 1.51e-02 | 15 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
| GO:000703410 | Oral cavity | OSCC | vacuolar transport | 103/7305 | 157/18723 | 1.25e-11 | 4.44e-10 | 103 |
| GO:00164829 | Oral cavity | OSCC | cytosolic transport | 106/7305 | 168/18723 | 2.08e-10 | 5.90e-09 | 106 |
| GO:00068929 | Oral cavity | OSCC | post-Golgi vesicle-mediated transport | 71/7305 | 104/18723 | 1.37e-09 | 3.33e-08 | 71 |
| GO:00070418 | Oral cavity | OSCC | lysosomal transport | 69/7305 | 114/18723 | 2.62e-06 | 3.26e-05 | 69 |
| GO:00988769 | Oral cavity | OSCC | vesicle-mediated transport to the plasma membrane | 79/7305 | 136/18723 | 4.93e-06 | 5.58e-05 | 79 |
| GO:00421476 | Oral cavity | OSCC | retrograde transport, endosome to Golgi | 55/7305 | 91/18723 | 2.79e-05 | 2.59e-04 | 55 |
| GO:00068962 | Oral cavity | OSCC | Golgi to vacuole transport | 14/7305 | 20/18723 | 4.95e-03 | 1.94e-02 | 14 |
| GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
| GO:000703415 | Oral cavity | LP | vacuolar transport | 74/4623 | 157/18723 | 7.85e-10 | 3.70e-08 | 74 |
| GO:001619714 | Oral cavity | LP | endosomal transport | 98/4623 | 230/18723 | 1.65e-09 | 7.50e-08 | 98 |
| GO:001648214 | Oral cavity | LP | cytosolic transport | 69/4623 | 168/18723 | 2.03e-06 | 4.65e-05 | 69 |
| GO:000704114 | Oral cavity | LP | lysosomal transport | 49/4623 | 114/18723 | 1.38e-05 | 2.45e-04 | 49 |
| GO:000689214 | Oral cavity | LP | post-Golgi vesicle-mediated transport | 44/4623 | 104/18723 | 5.90e-05 | 8.05e-04 | 44 |
| GO:009887614 | Oral cavity | LP | vesicle-mediated transport to the plasma membrane | 53/4623 | 136/18723 | 1.54e-04 | 1.76e-03 | 53 |
| GO:00068961 | Oral cavity | LP | Golgi to vacuole transport | 12/4623 | 20/18723 | 8.24e-04 | 7.23e-03 | 12 |
| GO:004214713 | Oral cavity | LP | retrograde transport, endosome to Golgi | 36/4623 | 91/18723 | 1.20e-03 | 9.67e-03 | 36 |
| GO:00324564 | Oral cavity | LP | endocytic recycling | 28/4623 | 73/18723 | 6.61e-03 | 3.86e-02 | 28 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| VPS52 | SNV | Missense_Mutation | c.1019G>A | p.Ser340Asn | p.S340N | Q8N1B4 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| VPS52 | SNV | Missense_Mutation | c.1781N>G | p.Asn594Ser | p.N594S | Q8N1B4 | protein_coding | tolerated(0.95) | benign(0.046) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| VPS52 | SNV | Missense_Mutation | novel | c.580N>G | p.Arg194Gly | p.R194G | Q8N1B4 | protein_coding | tolerated(0.06) | benign(0) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| VPS52 | insertion | Frame_Shift_Ins | novel | c.1552_1553insTGCCTTCCTACCCAGAAAATTCGGTTTCC | p.Ser518LeufsTer57 | p.S518Lfs*57 | Q8N1B4 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| VPS52 | SNV | Missense_Mutation | novel | c.2060N>A | p.Arg687His | p.R687H | Q8N1B4 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| VPS52 | SNV | Missense_Mutation | novel | c.214G>C | p.Glu72Gln | p.E72Q | Q8N1B4 | protein_coding | tolerated(0.13) | benign(0.353) | TCGA-EA-A5ZE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| VPS52 | SNV | Missense_Mutation | c.2121C>G | p.Ile707Met | p.I707M | Q8N1B4 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| VPS52 | SNV | Missense_Mutation | rs375033520 | c.8N>T | p.Ala3Val | p.A3V | Q8N1B4 | protein_coding | tolerated_low_confidence(0.15) | benign(0.235) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| VPS52 | SNV | Missense_Mutation | rs535462681 | c.476N>A | p.Arg159Gln | p.R159Q | Q8N1B4 | protein_coding | tolerated(0.45) | benign(0.014) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| VPS52 | SNV | Missense_Mutation | c.1264A>G | p.Thr422Ala | p.T422A | Q8N1B4 | protein_coding | tolerated(0.12) | benign(0.134) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |